Related references
Note: Only part of the references are listed.Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program
Hilary A. Robbins et al.
ANNALS OF EPIDEMIOLOGY (2023)
The blood proteome of imminent lung cancer diagnosis
Demetrius Albanes et al.
NATURE COMMUNICATIONS (2023)
Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment
Johannes F. Fahrmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The CDCP1 Signaling Hub: A Target for Cancer Detection and Therapeutic Intervention
Tashbib Khan et al.
CANCER RESEARCH (2021)
Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer
Sonia Dagnino et al.
CANCER RESEARCH (2021)
Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study
Rianne D. W. Vaes et al.
CANCERS (2021)
Survival disparities following surgery among patients with different histological types of non-small cell lung cancer
Horiana B. Grosu et al.
LUNG CANCER (2020)
Multiple health behaviors before and after a cancer diagnosis among women: A repeated cross-sectional analysis over 15 years
Daniel N. Tollosa et al.
CANCER MEDICINE (2020)
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis
Ticiana A. Leal et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
Joanna Kapeleris et al.
FRONTIERS IN ONCOLOGY (2018)
Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer
Xizhao Sui et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer
Kari Chansky et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma
Claire L. Meaney et al.
ONCOTARGET (2017)
Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer
Jordan A. Torok et al.
CLINICAL LUNG CANCER (2017)
Comprehensive evaluation of published gene expression prognostic signatures for biomarker-based lung cancer clinical studies
H. Tang et al.
ANNALS OF ONCOLOGY (2017)
Prediction of distant recurrence in resected stage I and II lung adenocarcinoma
Beatrice Aramini et al.
LUNG CANCER (2016)
An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers
Ana I. Robles et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Prognostic value of circulating inflammatory factors in non-small cell lung cancer: A systematic review and meta-analysis
Chen Liao et al.
CANCER BIOMARKERS (2014)
Oncogenic Ras/ERK Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis
Takamasa Uekita et al.
MOLECULAR CANCER RESEARCH (2014)
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial
Vanesa Gregorc et al.
LANCET ONCOLOGY (2014)
Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer
C. Bodelon et al.
ANNALS OF ONCOLOGY (2013)
Executive Summary Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Frank C. Detterbeck et al.
CHEST (2013)
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2013)
High circulating VEGF level predicts poor overall survival in lung cancer
Pingping Hu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
A New Measure of the Effective Number of Tests, a Practical Tool for Comparing Families of Non-Independent Significance Tests
Nicholas W. Galwey
GENETIC EPIDEMIOLOGY (2009)
Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer
Mohammad Chakra et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study
Fumiko Taguchi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen
JD Hooper et al.
ONCOGENE (2003)
Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates
FY Hsieh et al.
CONTROLLED CLINICAL TRIALS (2000)
Share Paper
